Fig. 6
Pharmacological deactivation of FTO sensitizes TKI resistant cells to TKI in vitro and in vivo. a, b CCK-8 (a) or colony-forming (b) assays for resistant cells treated with 25 µM rhein for 6 h followed by co-treatment with the FTO inhibitor plus varying concentrations of nilotinib for 72 h. The combination effects were normalized to DMSO only. c, d Dotblotting (c) or qPCR (d) of K562 nilotinibR cells treated with 25 µM rhein for 6 h followed by 1 µM nilotinib treatment for another 48 h. e Left, the images are the external view of tumors and the measurement of xenograft tumor weight; right, growth curve indicates the tumor volume. f Representative images of H&E and IHC staining of tumor sections. Window stands for the enlarged cells. g Graphs are the quantification of IHC-stained tumor sections. h The graph illustrates the average body weight of tumor-bearing mice. i Representative images of m6A dotblotting and the quantification of dot intensities in tumors. j qPCR for expression of indicated genes in tumors. Data in CCK-8 assays represent two independent experiments with 8 repeats; Data in colony assays represent two independent experiments with four repeats in total; In e–j, n = 6 tumors/ group; Data are mean ± SD; *p < 0.05, **p < 0.01. See also Figure S7
